Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385578275> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4385578275 endingPage "iii30" @default.
- W4385578275 startingPage "iii30" @default.
- W4385578275 abstract "Abstract We engineered a HER2 Ab that inhibited HER2+ breast cancer cell growth in vitro and led to a profound increase in Ab-dependent CD16A receptor stimulation relative to trastuzumab, the standard of care. Blood-brain barrier penetrant AAV vectors were administered intravenously to mice orthotopically engrafted with HER2+ cancer cells. In both prophylactic AAV administration and a treatment model where AAV was dosed post-engraftment, the vectorized Ab significantly reduced tumor burden and prolonged survival. We employed single-cell RNA-Seq to characterize immune responses to these vectorized Abs. Upon dissociation of brains from tumor engrafted mice that underwent intravenous AAV treatment, we performed transcriptomic profiling of CD45+ immune cells. Our results indicate a pronounced innate immune response to the HER2 Ab that increased tumor-proximal natural killer cells and proliferating microglia. Response to gene therapy also included dendritic cells that are mediators of adaptive immune activation. Therefore, the adaptive immune system could augment the efficacy of the therapy when non-exhausted, tumor-associated T lymphocytes are present. To minimize potential neuronal toxicity, we evaluated the use of a GFAP promoter for astrocyte specific expression. Furthermore, to reduce patient risk of cardiac toxicity induced by antibody exposure, we engineered the Fc domain of the antibody so that it would not bind to FcRN, a receptor which promotes antibody recycling and subsequent increased antibody levels in the periphery. In mouse studies, treatment with a BBB-penetrant capsid with a GFAP driven construct and with binding to FcRN eliminated resulted in a 96% reduction in serum antibody levels, to 84% below an estimated cardiac toxicity threshold. Additionally, there was a 78% reduction in antibody levels in the heart, to 98% below an estimated cardiac toxicity threshold. Remarkably, brain levels were maintained. Our animal data indicate that vectorized HER2 antibody gene transfer may address unmet medical needs of patients." @default.
- W4385578275 created "2023-08-05" @default.
- W4385578275 creator A5017502058 @default.
- W4385578275 creator A5019681303 @default.
- W4385578275 creator A5020508512 @default.
- W4385578275 creator A5027353457 @default.
- W4385578275 creator A5050813478 @default.
- W4385578275 creator A5060428505 @default.
- W4385578275 creator A5060553768 @default.
- W4385578275 creator A5092600804 @default.
- W4385578275 date "2023-08-01" @default.
- W4385578275 modified "2023-09-25" @default.
- W4385578275 title "SYST-13 AAV VECTOR ENCODING FC MODIFIED HER2 ANTIBODIES REDUCES TUMOR BURDEN WITH MINIMIZED PERIPHERAL EXPOSURE IN MODELS OF BREAST CANCER BRAIN METASTASIS" @default.
- W4385578275 doi "https://doi.org/10.1093/noajnl/vdad070.117" @default.
- W4385578275 hasPublicationYear "2023" @default.
- W4385578275 type Work @default.
- W4385578275 citedByCount "0" @default.
- W4385578275 crossrefType "journal-article" @default.
- W4385578275 hasAuthorship W4385578275A5017502058 @default.
- W4385578275 hasAuthorship W4385578275A5019681303 @default.
- W4385578275 hasAuthorship W4385578275A5020508512 @default.
- W4385578275 hasAuthorship W4385578275A5027353457 @default.
- W4385578275 hasAuthorship W4385578275A5050813478 @default.
- W4385578275 hasAuthorship W4385578275A5060428505 @default.
- W4385578275 hasAuthorship W4385578275A5060553768 @default.
- W4385578275 hasAuthorship W4385578275A5092600804 @default.
- W4385578275 hasBestOaLocation W43855782751 @default.
- W4385578275 hasConcept C121608353 @default.
- W4385578275 hasConcept C126322002 @default.
- W4385578275 hasConcept C159654299 @default.
- W4385578275 hasConcept C203014093 @default.
- W4385578275 hasConcept C2776914184 @default.
- W4385578275 hasConcept C2777701055 @default.
- W4385578275 hasConcept C2779830541 @default.
- W4385578275 hasConcept C502942594 @default.
- W4385578275 hasConcept C530470458 @default.
- W4385578275 hasConcept C71924100 @default.
- W4385578275 hasConcept C86803240 @default.
- W4385578275 hasConcept C8891405 @default.
- W4385578275 hasConceptScore W4385578275C121608353 @default.
- W4385578275 hasConceptScore W4385578275C126322002 @default.
- W4385578275 hasConceptScore W4385578275C159654299 @default.
- W4385578275 hasConceptScore W4385578275C203014093 @default.
- W4385578275 hasConceptScore W4385578275C2776914184 @default.
- W4385578275 hasConceptScore W4385578275C2777701055 @default.
- W4385578275 hasConceptScore W4385578275C2779830541 @default.
- W4385578275 hasConceptScore W4385578275C502942594 @default.
- W4385578275 hasConceptScore W4385578275C530470458 @default.
- W4385578275 hasConceptScore W4385578275C71924100 @default.
- W4385578275 hasConceptScore W4385578275C86803240 @default.
- W4385578275 hasConceptScore W4385578275C8891405 @default.
- W4385578275 hasIssue "Supplement_3" @default.
- W4385578275 hasLocation W43855782751 @default.
- W4385578275 hasOpenAccess W4385578275 @default.
- W4385578275 hasPrimaryLocation W43855782751 @default.
- W4385578275 hasRelatedWork W1996150995 @default.
- W4385578275 hasRelatedWork W2068428998 @default.
- W4385578275 hasRelatedWork W2107710620 @default.
- W4385578275 hasRelatedWork W2902226291 @default.
- W4385578275 hasRelatedWork W3036731669 @default.
- W4385578275 hasRelatedWork W3216801484 @default.
- W4385578275 hasRelatedWork W4306763567 @default.
- W4385578275 hasRelatedWork W4324028954 @default.
- W4385578275 hasRelatedWork W4360983034 @default.
- W4385578275 hasRelatedWork W4382653087 @default.
- W4385578275 hasVolume "5" @default.
- W4385578275 isParatext "false" @default.
- W4385578275 isRetracted "false" @default.
- W4385578275 workType "article" @default.